摘要:
The invention provides a novel oxazolidinone derivative represented by the formula (I): wherein Ring A, X1, Ring B and R1 are as described in the description, and an antibacterial agent containing the same.
摘要:
A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid.
摘要:
A medicament for promoting memory consolidation, which comprises, as an active ingredient, a non-natural retinoid, preferably a retinoid having a basic skeleton comprising an aromatic ring bound with an aromatic carboxylic acid or tropolone by means of a bridging group, more preferably 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or 4-[(3,5-bis-trimethylsilylphenyl)-carboxamido]benzoic acid.
摘要:
The invention provides a novel oxazolidinone derivative represented by the formula (I): wherein Ring A is optionally substituted or fused and represents (A-1) at least 7-membered monocyclic hetero ring containing at least three N atoms; (A-2) at least 6-membered monocyclic hetero ring containing at least two N atoms and at least one O atom; or (A-3) at least 7-membered monocyclic hetero ring containing at least two N atoms and at least one S atom; X1 is a single bond, —O—, —S—, —NR2—, —CO—, —CS—, —CONR3—, —NR4CO—, —SO2NR5—, and —NR6SO2— (wherein R2-R6 are independently hydrogen or lower alkyl), or lower alkylene or lower alkenylene in which one of the preceding groups may intervene; Ring B is optionally substituted carbocycle or optionally substituted heterocycle; R1 is hydrogen, or an organic residue which is able to bind to the 5-position of oxazolidinone ring in oxazolidinone antimicrobial agent, and an antibacterial agent containing the same.
摘要翻译:本发明提供由式(I)表示的新型恶唑烷酮衍生物:其中环A任选被取代或稠合并且代表(A-1)含有至少三个N原子的至少七元单环杂环; (A-2)至少含有至少两个N原子和至少一个O原子的6元单环杂环; 或(A-3)至少含有至少两个N原子和至少一个S原子的7元单环杂环; X 1是单键,-O - , - S - , - NR 2 - , - CO - , - C - , - CONR 3 - , - NR 4 CO-,-SO 2 NR 5 - 和-NR 6 SO 2 - 或低级烷基)或其中一个前述基团可以介入的低级亚烷基或低级亚烯基; 环B是任选取代的碳环或任选取代的杂环; R1是氢,或能够与恶唑烷酮抗微生物剂中的恶唑烷酮环的5位结合的有机残基,以及含有该残基的抗菌剂。
摘要:
A compound represented by the following general formula (I): [wherein R1 represents hydrogen atom or a C1-6 alkyl group, A and B represent —(CH2)2—, —(CH2)3— or —(CH2)4—, X represents —N(R2)— (R2 represents hydrogen atom or a C1-6 alkyl group), —CO—, —C(═N—R3)— (R3 represents hydrogen atom or a C1-6 alkyl group), or —C(═C(R4)(R5))— (R4 and R5 independently represent hydrogen atom or a C1-6 alkyl group), and Ar represents an aryldiyl group or a heteroaryldiyl group], which has an action of controlling physiological activities of retinoids and useful as an active ingredient of a medicament.
摘要:
A medicament having an anti-wrinkle action, which comprises as an active ingredient a retinoid having a fundamental structure of a phenyl substituted carbamoyl benzoic acid or a phenyl substituted carboxamide benzoic acid (for example, 4-(3,5-bis(trimethylsilyl)phenylcarboxamide) benzoic acid, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid, or the like).
摘要:
The present invention provides a novel oxazolidinone derivative of the formula (I): wherein Ring A is (A-1) a 7-membered monocyclic heterocycle containing three N atoms; (A-2) a 7-membered monocyclic heterocycle containing two N atoms and one O atom; or (A-3) a 7-membered monocyclic heterocycle containing two N atoms and one S atom, SO or SO2, wherein said monocyclic heterocycle is optionally substituted, optionally unsaturated and optionally fused with another ring; X1 is a single bond, or a heteroatom-containing group selected from the group consisting of —O—, —S—, —NR2—, —CO—, —CS—, —CONR3—, —NR4CO—, —SO2NR5—, and —NR6SO2—, wherein R2, R3, R4, R5 and R6 are independently hydrogen or lower alkyl, or lower alkylene or lower alkenylene each optionally interrupted by said heteroatom-containing group; Ring B is optionally substituted carbocycle or optionally substituted heterocycle; and R1 is hydrogen, or an organic residue which is able to bind to the 5-position of the oxazolidinone ring in oxazolidinone antimicrobial agents, pharmaceutically acceptable salts and solvates thereof which are useful as an antibacterial agent.
摘要翻译:本发明提供式(I)的新型恶唑烷酮衍生物:其中环A为(A-1)含有三个N原子的7-元单环杂环; (A-2)含有两个N原子和一个O原子的7-元单环杂环; 或(A-3)含有两个N原子和一个S原子,SO或SO 2的7-元单环杂环,其中所述单环杂环任选被取代,任选地不饱和且任选地与另一个环稠合; X 1为单键或选自-O - , - S - , - NR 2 - , - CO - , - CS - , - CONR 3 - , - NR 4 CO - , - SO 2 NR 5 - 和-NR 6 SO 2 - ,其中R 2,R 3,R 4,R 5和R 6独立地为氢或低级烷基,或低级亚烷基或低级亚烯基,各自任选被所述含杂原子基团中断; 环B是任选取代的碳环或任选取代的杂环; R 1为氢,或可用于作为抗菌剂使用的恶唑烷酮抗微生物剂,其药学上可接受的盐和溶剂合物中的恶唑烷酮环的5位的有机残基。
摘要:
A medicament for prophylactic and/or therapeutic treatment of a vascular disease such as vascular restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty using an intravascular stent, which comprises as an active ingredient a substance selected from the group consisting of retinoids and agents for controlling actions of retinoids such as 4-[5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid or a salt thereof, or 4-[[[3,5-bis-(trimethylsilyl)phenyl]carbonyl]amino]benzoic acid or a salt thereof, wherein said substance has substantially no antiproliferative action on vascular endothelial cells, but substantially has antiproliferative action on vascular smooth muscle cells.
摘要:
A medicament for preventive and/or therapeutic treatment of a secretory dysfunctional disease associated with lymphocyte infiltration into a gland such as type I diabetes or Sjogren's syndrome, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.
摘要:
A medicament for therapeutic and/or preventive treatment of restenosis or reocclusion after a vascular recanalization operation, which comprises as an active ingredient a compound represented by the following formula or a physiologically acceptable salt thereof, and a medical device for an intravascular treatment, which contains said compound or the physiologically acceptable salt thereof in a releasable form.